LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: Translation and cross-cultural adaptation of coping with rheumatic stressors instrument into Turkish language.

    Ayan, Gizem / Ramiro, Sofia / Pimentel-Santos, Fernando M / van Lankveld, Wim / Kilic, Levent

    International journal of rheumatic diseases

    2023  Volume 26, Issue 6, Page(s) 1183–1186

    MeSH term(s) Humans ; Cross-Cultural Comparison ; Language ; Translations ; Adaptation, Psychological ; Surveys and Questionnaires ; Reproducibility of Results ; Psychometrics
    Language English
    Publishing date 2023-01-25
    Publishing country England
    Document type Letter
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.14577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The effects of physical exercise on axial spondyloarthritis - a systematic review.

    Pina Gonçalves, Nuno / Emília Santos, Mariana / Silvério-António, Manuel / Donato, Helena / Pimentel-Santos, Fernando M / Cruz, Eduardo

    ARP rheumatology

    2023  

    Abstract: Aim: To collect and summarize the available scientific evidence that evaluates the effects of physical exercise interventions on axial spondyloarthritis (axSpA).: Methods: A systematic review was conducted in accordance to the guidance of Preferred ... ...

    Title translation The effects of physical exercise on axial spondyloarthritis – a systematic review.
    Abstract Aim: To collect and summarize the available scientific evidence that evaluates the effects of physical exercise interventions on axial spondyloarthritis (axSpA).
    Methods: A systematic review was conducted in accordance to the guidance of Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) to collect randomized controlled trials on the PubMed, Embase and Web of Science Core Collection databases. The search strategy included terms regarding physical exercise interventions targeted to axSpA participants and all of its variants in multiple combinations adapted to each one of the databases regarding its own special requirements. Several outcomes were defined: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), the 36-item short form health survey (SF-36) and the Ankylosing Spondylitis Quality of Life questionnaire (ASQoL). Two independent researchers screened the titles and abstracts followed by full-text analysis when suitable, using EndnoteTM online. Selected articles, according to exclusion/inclusion criteria defined, were submitted to data extraction and bias assessment was performed for each study's outcomes using the Cochrane risk-of-bias tool for randomized trials.
    Results: A total of 2063 articles were identified through the electronic databases search. After removal of duplicates, 1435 were eligible for screening, of which 45 articles went through full text evaluation. Only 24 articles met the inclusion/exclusion criteria. Physical exercise contributes for a statistically significant improvement of BASDAI in 13 studies, BASFI in 10, BASMI in 6, ASDAS in 3, CRP in 2, ESR in 1, SF-36 in 2 and ASQoL in 3.No major adverse effects were reported and an overall benefit was noted with the implementation of physical exercise as a treatment modality for axSpA.
    Conclusion: Physical exercise seems to be an effective non-pharmacological therapy for axSpA, with positive effects in disease activity, physical function, and quality of life.
    Language English
    Publishing date 2023-08-27
    Publishing country Portugal
    Document type Journal Article
    ISSN 2795-4552
    ISSN (online) 2795-4552
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Determinants of health-related quality of life and global functioning and health in axSpA, pSpA, and PsA: results from the ASAS-PerSpA study.

    Santos, Helena / Henriques, Ana R / Machado, Pedro M / Lopez-Medina, Clementina / Dougados, Maxime / Canhão, Helena / Rodrigues, Ana M / Pimentel-Santos, Fernando M

    Rheumatology (Oxford, England)

    2023  

    Abstract: Objectives: We aim to identify determinants of health-related quality of life (HRQoL) and global functioning and health (GH) in axial spondyloarthritis (axSpA), peripheral spondyloarthritis (pSpA), and psoriatic arthritis (PsA).: Methods: ASAS-perSpA ...

    Abstract Objectives: We aim to identify determinants of health-related quality of life (HRQoL) and global functioning and health (GH) in axial spondyloarthritis (axSpA), peripheral spondyloarthritis (pSpA), and psoriatic arthritis (PsA).
    Methods: ASAS-perSpA study data were analyzed. Models for the three patient groups were performed separately to explore factors associated with HRQoL and GH, assessed by EQ-5D and ASAS-HI, respectively.
    Results: The analyses included 4185 patients: 2719 with axSpA, 433 with pSpA, and 1033 with PsA.In axSpA, disease activity (DA) (β=-0.061), physical function (β=-0.041), female sex (β=-0.019), and fibromyalgia (β=-0.068) were associated with worse HRQoL; age (β = 0.001) and university education (β = 0.014) with better HRQoL. In pSpA, DA (β=-0.04) and physical function (β=-0.054) were associated with worse HRQoL. In PsA, DA (β=-0.045), physical function (β=-0.053), axial disease (β=-0.041), and female sex (β=-0.028) were associated with worse HRQoL.In axSpA, DA (β = 0.889), physical function (β = 0.887), peripheral disease (β = 0.564), female sex (β = 0.812) and fibromyalgia (β = 1.639) were associated with worse GH; age (β=-0.013) and university education (β=-0.274) with better GH. In pSpA, physical function (β = 1.142), and female sex (β = 1.060) were associated with worse GH; university education (β=-0.611) with better GH. In PsA, DA (β = 0.703), physical function (β = 1.025), axial involvement (β = 0.659), female sex (β = 0.924), and fibromyalgia (β = 1.387) were associated with worse GH; age (β=-0.024) and university education (β=-0.856) with better GH.
    Conclusions: DA and physical function are major HRQoL and GH determinants across spondyloarthritis types, and clinical characteristics and sociodemographic factors play an important role, highlighting the importance of a holistic approach for individual patients.
    Language English
    Publishing date 2023-09-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kead503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Muscle Evaluation in Axial Spondyloarthritis-The Evidence for Sarcopenia.

    Valido, Ana / Crespo, Carolina Lage / Pimentel-Santos, Fernando M

    Frontiers in medicine

    2019  Volume 6, Page(s) 219

    Abstract: Sarcopenia is a syndrome defined as a progressive and generalized skeletal muscle disorder associated with an increased likelihood of adverse outcomes such as falls, fractures, physical disability, and death. The actual definition of sarcopenia is based ... ...

    Abstract Sarcopenia is a syndrome defined as a progressive and generalized skeletal muscle disorder associated with an increased likelihood of adverse outcomes such as falls, fractures, physical disability, and death. The actual definition of sarcopenia is based on a reduction in the values of three parameters: strength, muscle mass quantity or quality, and physical performance (the determinant of severity). Muscle wasting is a common feature in several chronic diseases, such as spondyloarthritis (SpA), and significantly increases patient morbidity and mortality. Although there has been huge progress in this field over recent years, the absence of a clear definition and clear diagnostic criteria of sarcopenia has resulted in inconsistent information regarding muscle-involvement in SpA. Thus, the aim of this review is to collect relevant evidence on muscular changes occurring during the disease process from the published literature, according to the recommended tools for sarcopenia evaluation proposed by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). In addition, data from histological, electromyography, and biochemical muscle analyses of SpA patients are also reviewed. Overall, a reduction in muscle strength with a systemic decrease in lean mass seems to be associated with a gait speed compromise. This information is usually fragmented, with no studies considering the three parameters together. This paper represents a call-to-action for the design of new studies in the future.
    Language English
    Publishing date 2019-10-18
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2019.00219
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Health-related quality of life among spondyloarthritis and chronic low back pain patients: results from a nationwide population-based survey.

    Santos, Helena / Henriques, Ana Rita / Branco, Jaime / Machado, Pedro M / Canhão, Helena / Pimentel-Santos, Fernando M / Rodrigues, Ana Maria

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

    2022  Volume 32, Issue 2, Page(s) 383–399

    Abstract: Purpose: Both spondyloarthritis and chronic low back pain (CLBP) significantly impact health-related quality of life (HRQoL). It is important to clarify whether these disorders have different impacts on the several domains of HRQoL as different ... ...

    Abstract Purpose: Both spondyloarthritis and chronic low back pain (CLBP) significantly impact health-related quality of life (HRQoL). It is important to clarify whether these disorders have different impacts on the several domains of HRQoL as different mechanisms may necessitate different treatment interventions. Moreover, the factors associated with HRQoL can inform more targeted group interventions to promote HRQoL.
    Methods: We used data from EpiReumaPt, a population-based survey conducted from September 2011 to December 2013. HRQoL was assessed with EuroQoL-5-Dimensions (EQ-5D). Spondyloarthritis was diagnosed by expert opinion (rheumatologist) and predefined criteria. CLBP was diagnosed if low back pain was present on the day of the interview and persisted for > 90 days. Univariable and multivariable linear regression analyses compared HRQoL among subjects with spondyloarthritis, CLBP, and no rheumatic diseases. Multivariable linear regression analyses evaluated HRQoL factors in spondyloarthritis and CLBP subjects.
    Results: We included 92 spondyloarthritis patients, 1376 CLBP patients, and 679 subjects without rheumatic diseases. HRQoL was similarly affected in spondyloarthritis and CLBP (ß =  - 0.03, 95% CI [- 0.08; 0.03]) in all EQ5D dimensions. A much lower HRQoL was found in spondyloarthritis and CLBP patients compared with subjects without rheumatic diseases (ß =  - 0.14, 95% CI [- 0.19; - 0.10]; ß =  - 0.12, 95% CI [- 0.14; - 0.09], respectively). In spondyloarthritis subjects, multimorbidity and active disease were associated with worse HRQoL (ß =  - 0.18; 95% CI [- 0.24; 0.03]; ß =  - 0.13; 95% CI [- 0.29; - 0.05], respectively), and regular physical exercise was associated with better HRQoL (ß = 0.18; 95% CI [0.10; 0.30]). In CLBP subjects, multimorbidity (β =  - 0.11; 95% CI [- 0.14; - 0.08]), obesity (β =  - 0.04; 95% CI [- 0.08; - 0.01]), and low back pain intensity (β =  - 0.02; 95% CI [- 0.03; - 0.02]) were associated with worse HRQoL, and regular physical exercise (β = 0.08; 95% CI [0.05; 0.11]) was significantly associated with better HRQoL.
    Conclusion: Spondyloarthritis and CLBP subjects reported similar levels of impairment in the mental, physical, and social domains of HRQoL. Future health plans should address modifiable factors associated with HRQoL in these conditions to achieve better outcomes.
    MeSH term(s) Humans ; Quality of Life/psychology ; Low Back Pain/therapy ; Data Collection ; Spondylarthritis ; Regression Analysis ; Chronic Pain/therapy
    Language English
    Publishing date 2022-10-29
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1161148-0
    ISSN 1573-2649 ; 0962-9343
    ISSN (online) 1573-2649
    ISSN 0962-9343
    DOI 10.1007/s11136-022-03274-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors.

    Sobral, Daniel / Fernandes, Ana Filipa / Bernardes, Miguel / Pinto, Patrícia / Santos, Helena / Lagoas-Gomes, João / Tavares-Costa, José / Silva, José A P / Dias, João Madruga / Bernardo, Alexandra / Gaillard, Jean-Charles / Armengaud, Jean / Benes, Vladimir / Domingues, Lúcia / Maia, Sara / Branco, Jaime C / Coelho, Ana Varela / Pimentel-Santos, Fernando M

    Biomolecules

    2024  Volume 14, Issue 3

    Abstract: This study aims at identifying molecular biomarkers differentiating responders and non-responders to treatment with Tumor Necrosis Factor inhibitors (TNFi) among patients with axial spondyloarthritis (axSpA). Whole blood mRNA and plasma proteins were ... ...

    Abstract This study aims at identifying molecular biomarkers differentiating responders and non-responders to treatment with Tumor Necrosis Factor inhibitors (TNFi) among patients with axial spondyloarthritis (axSpA). Whole blood mRNA and plasma proteins were measured in a cohort of biologic-naïve axSpA patients (
    MeSH term(s) Humans ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Adalimumab/therapeutic use ; Spondylitis, Ankylosing ; Antirheumatic Agents/therapeutic use ; Tumor Necrosis Factor-alpha ; Treatment Outcome ; Axial Spondyloarthritis
    Chemical Substances Tumor Necrosis Factor Inhibitors ; Adalimumab (FYS6T7F842) ; Antirheumatic Agents ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2024-03-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom14030382
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: The Effect of

    Pimenta, Isabel / Mateus, Hugo / Rodrigues-Manica, Santiago / Pinheiro-Torres, Rita / Neto, Agna / Domingues, Lúcia / Lage Crespo, Carolina / Sardoo, Atlas / Machado, Pedro / Branco, Jaime C / Silva, Susana N / Pimentel-Santos, Fernando M

    Frontiers in genetics

    2021  Volume 12, Page(s) 688984

    Abstract: Background: Spondyloarthritis (SpA) are the most common group of chronic inflammatory rheumatic diseases affecting about 1.5% of the adult Caucasian population. Low back pain is the most common symptom. The aetiopathogenesis of SpA is multifactorial, ... ...

    Abstract Background: Spondyloarthritis (SpA) are the most common group of chronic inflammatory rheumatic diseases affecting about 1.5% of the adult Caucasian population. Low back pain is the most common symptom. The aetiopathogenesis of SpA is multifactorial, with well-known genetic and environmental contributions. Furthermore, muscle properties might also be involved in the pathophysiological process and these could be modulated by the genetic background.
    Methods: We performed a pilot study based on case-control approach involving 56 participants: 28 axSpA patients and 28 healthy controls matched by age, gender and levels of physical activity. Clinical, epidemiological and muscle characterization data-muscle physical properties (stiffness, tone, and elasticity), strength, mass, and performance, were collected. Two different muscles were considered for analysis, the Multifidus and Gastrocnemius. Four SNPs of
    Results: In total, 51 individuals (27 axSpA patients and 24 matched controls) were eligible for further genetic analysis, 66.7% being male and with a mean age of 36 years. Muscle physical properties, muscle strength and muscle mass were similar in both groups; however, axSpA patients showed a decrease in muscle performance. None of the studied SNPs were associated with disease susceptibility/phenotype, muscle physical properties, muscle strength or muscle mass. However,
    Conclusion: Our results suggest an association between
    Language English
    Publishing date 2021-08-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606823-0
    ISSN 1664-8021
    ISSN 1664-8021
    DOI 10.3389/fgene.2021.688984
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach.

    Francisco, Rita / Pascoal, Carlota / Marques-da-Silva, Dorinda / Brasil, Sandra / Pimentel-Santos, Fernando M / Altassan, Ruqaiah / Jaeken, Jaak / Grosso, Ana Rita / Dos Reis Ferreira, Vanessa / Videira, Paula A

    Journal of clinical medicine

    2020  Volume 9, Issue 7

    Abstract: Congenital disorders of glycosylation (CDG) are rare diseases with variable phenotypes and severity. Immunological involvement remains a largely uncharted topic in CDG, mainly due to lack of robust data. To better characterize immune-related ... ...

    Abstract Congenital disorders of glycosylation (CDG) are rare diseases with variable phenotypes and severity. Immunological involvement remains a largely uncharted topic in CDG, mainly due to lack of robust data. To better characterize immune-related manifestations' prevalence, relevance, and quality-of-life (QoL) impact, we developed electronic questionnaires targeting (1) CDG patients and (2) the general "healthy" population. Two-hundred and nine CDG patients/caregivers and 349 healthy participants were included in this study. PMM2-CDG was the most represented CDG (
    Language English
    Publishing date 2020-07-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9072092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.

    Cruz-Machado, Ana Rita / Rodrigues-Manica, Santiago / Silva, Joana Leite / Alho, Irina / Coelho, Constança / Duarte, Joana / Florêncio, Cláudia / Pimentel-Santos, Fernando M / Tavares-Costa, José / Vieira-Sousa, Elsa

    Rheumatology (Oxford, England)

    2020  Volume 59, Issue 11, Page(s) 3158–3171

    Abstract: Objectives: To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission- ...

    Abstract Objectives: To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA).
    Methods: Data from randomized controlled trials (RCTs), including long-term extensions, were included. A systematic literature review was performed using the MEDLINE database (first search May 2018, updated February 2020) and PICO criteria according to Patients-adults with radiographic or non-radiographic axSpA; Intervention-any bDMARD; Comparator-placebo and/or any different drug; Outcomes-ASAS-PR and/or ASDAS-ID as primary or secondary endpoints. Meta-analysis was performed after assessment of the homogeneity of study designs, populations and outcomes.
    Results: After screening 155 references, a total of 22 RCTs and 28 long-term extensions were retrieved. ASAS-PR was the dominant remission-like definition used. Concerning TNF inhibitors, 14/17 RCTs provided evidence of efficacy in reaching remission at different time points: 12, 16, 24 and 28 weeks (ASAS-PR in 16-62% of patients and ASDAS-ID in 24-40% of patients). With a limited number of studies available, IL-17A inhibitors exhibited remission rates of 15-21% for ASAS-PR and 11-16% for ASDAS-ID at week 16. A meta-analysis regarding ASAS-PR was performed considering RCTs with a similar duration (12, 16 or 24 weeks). The relative risk for achieving remission was 3.864 (95% CI 2.937, 5.085).
    Conclusion: bDMARDs have a clear impact in axSpA remission evaluated by ASAS-PR. Nevertheless, these data show an unmet need for improved reporting of remission-like outcomes.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Humans ; Randomized Controlled Trials as Topic ; Remission Induction ; Spondylarthritis/drug therapy
    Chemical Substances Antirheumatic Agents
    Language English
    Publishing date 2020-07-21
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keaa268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action.

    Rodrigues-Manica, Santiago / Silva, Joana / Cruz-Machado, Rita / Coelho, Constança / Duarte, Joana / Vieira-Sousa, Elsa / Tavares-Costa, José / Pimentel-Santos, Fernando M

    Clinical rheumatology

    2020  Volume 40, Issue 1, Page(s) 33–41

    Abstract: This paper is to assess the efficacy of different biologic DMARDs (bDMARDs) on several patient-reported outcomes (PROs) in randomized controlled trials (RCT) in axial spondyloarthritis (axSpA). A systematic literature review (SLR) was performed. MEDLINE ( ...

    Abstract This paper is to assess the efficacy of different biologic DMARDs (bDMARDs) on several patient-reported outcomes (PROs) in randomized controlled trials (RCT) in axial spondyloarthritis (axSpA). A systematic literature review (SLR) was performed. MEDLINE (May 1, 2018) was used with the filters "published in the last 10 years" and "humans." The PICO criteria used were Patients: adults with radiographic axSpA (r-axSpA) or non-radiographic axSpA (nr-axSpA); Intervention: any bDMARD; Compararator: placebo (PBO)/any different drug; Outcome: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL), the EuroQol-5D (EQ-5D), the Short Form 36 Health Survey physical component summary (SF36-PCS), the Short Form 36 Health Survey mental component summary (SF36-MCS), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). After screening 84 initial references and manually selecting other 9, 24 publications, assessing TNF inhibitors (TNFi) or IL17A inhibitors (IL17Ai) were selected. Four RCTs quantified the minimal clinical important difference (MCID) between treatment arms. Most of the RCTs compared the mean difference of PROs between different timepoints. Overall, the treatment arm was superior to the comparator. PROs were often underreported or highly heterogeneously presented. MCID was seldom mentioned. There is a need to raise the standard of care on SpA by aiming at remission and PRO associated improvements. In order to achieve this goal, the target must be clearly defined, reported, and tested.
    MeSH term(s) Adult ; Antirheumatic Agents/therapeutic use ; Biological Products/therapeutic use ; Humans ; Patient Reported Outcome Measures ; Spondylarthritis/drug therapy ; Spondylitis, Ankylosing/drug therapy
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2020-06-12
    Publishing country Germany
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-020-05209-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top